Article: Boston Biomedica Announces the Availability of a New Test for Lyme Disease.

BBI Clinical Laboratories Will Be First To Offer The 3rd Generation Test

WEST BRIDGEWATER, Mass., Aug. 28 /PRNewswire/ --

Boston Biomedica, Inc. (Nasdaq: BBII) announced today that BBI Clinical Laboratories of New Britain, CT (a wholly-owned subsidiary of Boston Biomedica) has launched a new antibody test for Lyme Disease called the C6 Lyme Peptide ELISA (VlsE). There is a nationwide market for Lyme Disease testing, but accurate diagnosis has been hampered to date by inadequate tests. The Company believes that this new test offers a significant breakthrough in accuracy. BBI Clinical Laboratories is the first reference laboratory to make this test ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!